Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT03106415 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03106415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03106415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
September 27, 2017
Completion date
May 19, 2022
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, metastatic triple-negative breast carcinoma, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7